Live Breaking News & Updates on Innovent Biologics

Stay updated with breaking news from Innovent biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology. ....

Rhui Zhou , Adimab Incyte , Eli Lilly , Innovent Biologics , National Medical Products Administration , Prnewswire Innovent Biologics Inc , Md Anderson Cancer Center , Drug Administration , Receives Fast Track Designation , Advanced Pancreatic , Fast Track Designation , Senior Vice President , Track Designation ,

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes. ....

United States , Adimab Incyte , Innovent Biologics , Eli Lilly , Linong Ji , University People Hospital , Clinical Development Of Innovent , Company Lilly , Prnewswire Innovent Biologics Inc , American Diabetes Association , Md Anderson Cancer Center , Scientific Sessions , Chinese Participants , Poster Theater , Peking University People , Liver Steatosis , Chinese Adults , Lei Qian , Vice President , Clinical Development ,

CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp...

....

United States , Innovent Biologics , Bristol Myers Squibb , Akeso Biopharma , Drugs Under Different Phases Of Clinical Development , Pharmaceuticals Inc , Drug Administration , University Collaborations Licensing Partnering Analysis , Alpine Immune Sciences , Akeso Biopharma Co Ltd , Route Of Administration , Biocytogen Pharmaceuticals , Inhibitors Companies , Molecular Templates Inc , Akeso Inc , Key Companies , Chia Tai Tianqing Pharmaceutical Group Co Ltd , Competitive Landscape , Clinical Trials , Competitive Landscape Insight , Pipeline Insight , Competitive Landscape Report , Shanghai Henlius Biotech , Harbour Biomed , Alphamab Oncology , Molecular Templates ,

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company… ....

Rhui Zhou , United States , Hong Kong , Sanofi Incyte , Eli Lilly , Wei Li , Innovent Biologics , Caicun Zhou , China National Medical Products Administration , Md Anderson Cancer Center , Drug Administration , National Medical Products Administration , Innovent Or Company , Department Of Oncology At Shanghai East Hospital , Tongji University , Innovent Biologics Inc , American Society Of Clinical Oncology , Clinical Oncology , Drug Evaluation , Principal Investigator , Shanghai East Hospital , Senior Vice President , Breakthrough Therapy Designations , Priority Review Designations , New Drug Applications , Anheart Therapeutics ,

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut ....

Rhui Zhou , Hong Kong , United States , Eli Lilly , Innovent Biologics , Caicun Zhou , Sanofi Incyte , Wei Li , Drug Administration , National Medical Products Administration , Department Of Oncology At Shanghai East Hospital , Innovent Or Company , Tongji University , China National Medical Products Administration , Md Anderson Cancer Center , American Society Of Clinical Oncology , Prnewswire Innovent Biologics Inc , Innovent Biologics Inc , Clinical Oncology , Drug Evaluation , Principal Investigator , Shanghai East Hospital , Senior Vice President , Breakthrough Therapy Designations , Priority Review Designations , New Drug Applications ,